Menu Search
Equities

Genomma Lab Internacional SAB de CV

LABB:MEX

Genomma Lab Internacional SAB de CV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (MXN)16.91
  • Today's Change-0.37 / -2.14%
  • Shares traded2.45m
  • 1 Year change+11.32%
  • Beta0.6074
Data delayed at least 20 minutes, as of May 14 2024 21:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in MXNIncome statement in MXNView more

Year on year Genomma Lab Internacional SAB de CV's net income fell -21.90% from 1.39bn to 1.08bn despite relatively flat revenues.
Gross margin62.23%
Net profit margin6.67%
Operating margin20.10%
Return on assets5.09%
Return on equity10.91%
Return on investment8.21%
More ▼

Cash flow in MXNView more

In 2023, Genomma Lab Internacional SAB de CV increased its cash reserves by 14.67%, or 190.39m. The company earned 2.25bn from its operations for a Cash Flow Margin of 13.65%. In addition the company used 302.21m on investing activities and also paid 1.68bn in financing cash flows.
Cash flow per share1.41
Price/Cash flow per share13.14
Book value per share10.34
Tangible book value per share4.65
More ▼

Balance sheet in MXNView more

Genomma Lab Internacional SAB de CV has a Debt to Total Capital ratio of 39.45%, a higher figure than the previous year's 14.23%.
Current ratio1.61
Quick ratio1.32
Total debt/total equity0.6516
Total debt/total capital0.3945
More ▼

Growth rates in MXN

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -22.94% and -18.98%, respectively. Additionally, five year annualized earnings per share growth ranks highest in its industry.
Div yield(5 year avg)2.09%
Div growth rate (5 year)--
Payout ratio (TTM)54.59%
EPS growth(5 years)0.8978
EPS (TTM) vs
TTM 1 year ago		-20.16
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.